Pramod K. Mistry, MD, PhD, FRCP; Elena Lukina, MD; Hadhami Ben Turkia, MD; et al.
This international randomized clinical trial found that among adults with Gaucher disease type 1, treatment with eliglustat for 9 months resulted in significant improvements in spleen volume, hemoglobin level, liver volume, and platelet count compared with placebo.